Table 9. Phase II and III of topotecan.
| Reference | N | Regimen | RR | Median survival | Survival (at year) | Disease/line of treatment |
|---|---|---|---|---|---|---|
| Schiller79 | 48 | 2 mg/m2 d1–5 q3w | 39% | 10 m | 39% (1y) | First |
| Ardizzoni80 | 47 | 1.5 mg/m2 d1–5 q3w | 6.4% | 4.7 m | 6.4% (1y) | Ref |
| 45 | 37.8% | 6.9 m | 33% (1y) | Rel | ||
| P value | 0.002 | |||||
| Eckardt81 | 38 | 1.5 mg/m2 d1–5 q3w | 3% | 4.8 m | NR | Ref |
| 36 | 19% | 6 m | NR | Rel | ||
| Von Pawel82 | 52 | Oral | 23% | 7.4 m | NR | Rel |
| 54 | IV | 15% | 5.8 m | NR | Rel | |
| Perez-Soler83 | 32 | 1.25 mg/m2 d1–5 q3w | 11% | 4.6 m | NR | Ref |
| Christodo84 | 34 | T 0.9 mg/m2 and P 20 mg/m2 | 18% | 6.5 m | NR | Ref |
| (all d1–3 all/3w) | Rel | |||||
| Quoix85 | 41 | T 1.25 mg/m2 d1–5 and P 50 mg/m2 d5 | 63% | 9.6 m | NR | First |
| 41 | T 0.75 mg/m2 and E 60 mg/m2 (all d1–5) (all/3w) | 61% | 10.1 m | |||
| P value | NS | NS | ||||
| Eckardt86 | 389 | T 1.7 mg/m2 (oral) and P 60 mg/m2 d5 | 63% | 9.2 m | 31% (1y) | First |
| 395 | P 80 mg/m2 d1 and E100 mg/m2 d1–3 | 68.9% | 9.4 m | 31% (1y) | ED | |
| NS | NS | NS | ||||
| Hobdy87 | 42 | T 1mg/m2 d1–5 and Cyclo 0.6 g/m2 d1 (all/3w) | 40.5% | 9 m | 21% (2y) | Rel |
| Ramalingam88 | 32 | T 1mg/m2 d1–5 and Taxol 135 mg/m2 d1 (all/3w) | 69% | 12.7 m | 50% (1y) | First |
| 10% (2y) | ||||||
| Von Pawel89 | 107 | T 1.5 mg/m2 d1–5 | 24.3% | 5.8 m | 14.2% (1y) | Rel |
| 104 | CAV | 18.3% | 5.8 m | 14.4% (1y) | ||
| P value | 0.285 | NS |
IV, intravenous; T, topotecan; P, cisplatin; E, etoposide; q, every; d, day; w, week.